EVMN
STRONG SHORTNeutralComposite
11.40
Technical
1.00
Fundamental
18.30
Rank
—
Price
12.10
Hurst
—
As of
Jul 14, 2026
Daily
Evommune, Inc.
HealthcareBiotechnologyEvommune is a clinical-stage biotech firm developing treatments for chronic inflammatory conditions. The company's lead candidates include EVO756, designed to address chronic spontaneous urticaria and atopic dermatitis, and EVO301, intended for atopic dermatitis and ulcerative colitis. Founded in 2020 and based in Palo Alto, California, the company focuses on novel therapeutic approaches to inflammatory disease mechanisms.
Market cap
$244.2M
P/E (trailing)
—
P/E (forward)
-1.89
PEG ratio
—
Dividend yield
0.00%
Beta
—
52w range
4.94 – 33.20
Return on equity
-52.11%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 6.73 (-66.7%) · range 5.10–31.57
Cycle position
4/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 73 · GOOD SETUP · exit proximity 0
Conviction
48/ 100 · maturity 0%
Buildup.3340
EMA entry setup.4273
Fundamentals.2518
Volume profile
POC
6.41
Price vs POC
+5.1%
Overhead supply
82%
Runway
+94.7%
Value area 4.94–14.57 · 82% of 120d volume overhead · heavy supply
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +16.37% | +19.89% | mature |
| 40d | -23.32% | +22.83% | mature |